4,245 Shares in CRISPR Therapeutics AG $CRSP Bought by Valeo Financial Advisors LLC

Key Points

• Valeo Financial Advisors LLC acquired 4,245 shares of CRISPR Therapeutics AG, valued at approximately $206,000, during the second quarter.
• CRISPR Therapeutics reported a loss of $1.29 earnings per share (EPS) for the last quarter, exceeding estimates but reporting significantly lower revenue compared to analyst expectations.
• Institutional investors own 69.20% of CRISPR Therapeutics' stock, reflecting a strong interest in this gene-editing company.

Valeo Financial Advisors LLC acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,245 shares of the company's stock, valued at approximately $206,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. IVC Wealth Advisors LLC purchased a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at about $225,000. Alta Wealth Advisors LLC purchased a new position in shares of CRISPR Therapeutics in the second quarter valued at $238,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of CRISPR Therapeutics by 18.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,336 shares of the company's stock valued at $162,000 after purchasing an additional 519 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its holdings in CRISPR Therapeutics by 2.0% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 23,195 shares of the company's stock worth $1,128,000 after buying an additional 450 shares in the last quarter. Finally, PFG Investments LLC lifted its holdings in CRISPR Therapeutics by 23.9% in the 2nd quarter. PFG Investments LLC now owns 12,896 shares of the company's stock worth $627,000 after buying an additional 2,487 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Stock Down 2.5%

NASDAQ:CRSP opened at $73.07 on Friday. The company has a market cap of $6.65 billion, a PE ratio of -13.46 and a beta of 1.84. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $78.48. The business's 50 day moving average is $59.14 and its two-hundred day moving average is $48.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $6.44 million. During the same period in the prior year, the company posted ($1.49) EPS. The business's revenue was up 72.5% compared to the same quarter last year. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director Simeon George purchased 989,812 shares of the firm's stock in a transaction dated Wednesday, July 16th. The stock was acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the acquisition, the director owned 1,730,179 shares of the company's stock, valued at approximately $90,021,213.37. This represents a 133.69% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Bank of America dropped their target price on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, September 23rd. Needham & Company LLC restated a "buy" rating and set a $81.00 price objective on shares of CRISPR Therapeutics in a research note on Friday. JPMorgan Chase & Co. assumed coverage on CRISPR Therapeutics in a research note on Thursday, September 18th. They set an "overweight" rating and a $70.00 target price for the company. Finally, JMP Securities reiterated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Ten equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, CRISPR Therapeutics has a consensus rating of "Hold" and a consensus price target of $71.50.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.